- New pill “Foundayo” works like Ozempic/Wegovy — but no injections required
- Clinical trials showed about 12% weight loss over 72 weeks
- Can be taken anytime, with or without food — easier than competing options
- The widely advertised “$25/month” price does NOT apply to Medicare
- Out-of-pocket cost runs $149–$349/month until Medicare coverage begins
- Medicare coverage is expected July 2026 — estimated ~$50/month, varies by plan
- Side effects and warnings are similar to other GLP-1 drugs
- Not a magic fix — still requires diet and lifestyle changes
A new weight-loss pill called Foundayo (orforglipron) just got FDA approval. It's a once-daily pill that works like the popular GLP-1 drugs Ozempic and Wegovy — no injections, no refrigeration, no needle anxiety.
In clinical trials, people on the highest dose lost an average of 12% of their body weight over 72 weeks. For a 200-pound person, that's 24 pounds.
Made by Eli Lilly, it's OK'ed for adults considered "obese" or who are overweight with at least one weight-related condition like high blood pressure or type 2 diabetes.
A competitive edge
One practical edge over its competitor Wegovy is that Foundayo can be taken any time of day, with or without food. The Wegovy pill requires an empty stomach and a 30-minute wait before eating. For older adults managing complicated morning routines (like when to eat), that's a real difference.
Carolyn Ames
Why It Matters for Seniors
Close to 3 in 4 Seniors are carrying excess weight. Losing even 10–15% of body weight can improve joint pain, blood sugar, blood pressure, and mobility. GLP-1 drugs have been effective at that — but weekly injections have kept a lot of older adults on the sidelines. A daily pill changes the equation.
FAQs: A Few Things Worth Knowing About Foundayo
Side effects are similar to other GLP-1 drugs: nausea, constipation, diarrhea, stomach discomfort. Most are manageable. Hair loss has also been reported.
There's a thyroid warning. Foundayo carries a boxed warning for potential thyroid tumors. If you or a family member has a history of medullary thyroid cancer or MEN2 syndrome, this drug isn't for you.
It's not a replacement for lifestyle changes. The FDA approved it alongside a reduced-calorie diet and increased physical activity — not instead of them.
Don't mix GLP-1 drugs. If you're already taking Ozempic, Mounjaro, or Wegovy, Foundayo isn't an add-on. Talk to your doctor.
Now, the Part the Headlines Are Glossing Over
You've probably seen "$25 a month" everywhere. Here's the scoop on that:
- Commercial insurance: $25/month with a Lilly savings card. That's the number getting all the attention.
- Out of pocket: $149–$349/month depending on dose.
- Medicare: The $25 savings card explicitly excludes Medicare Part D, Medicare Advantage, and Medigap enrollees. You're not eligible.
The better news: Medicare is expected to cover Foundayo at around $50/month for eligible Part D enrollees — but not until July 1, 2026 at the earliest. That $50 figure will also vary by plan. Your specific plan may or may not include it on its formulary.
Gary P Guthrie
In the Meantime...
- Talk to your doctor to see if you're a candidate.
- Wait until July if you're on Medicare, then call your plan to confirm coverage and your actual copay.
- Don't count on the $25 card — it's for commercially insured patients only.
Foundayo is a real step forward, especially for seniors who've avoided GLP-1 therapy because of the injections. Just make sure you know the actual price before you get excited.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Talk to your doctor or pharmacist before starting any new medication, including Foundayo. Pricing and Medicare coverage details are based on information available at the time of publication and may change.
Sources: FDA, Eli Lilly, CNN Health, AJMC, CDC/NCHS
